Dizhe Pharmaceuticals: Savolitinib has been approved in the U.S. but sales have not yet begun, so the new drug tariffs in the U.S. currently have no impact.

Acting as an investor, the reporter learned from the Securities Department of Dizhiyao Pharmaceutical that the company’s Suvotertin(Zegvrovvy) achieved U.S. listing last year, but has not yet been commercialized and sold in the United States. Therefore, the U.S. announcement that it will impose a 100% additional tariff on imported patented drugs and pharmaceutical ingredients will have no impact on the company. When asked whether it would affect commercialization expectations and pricing, the company replied, “Please wait for the subsequent announcement; it’s not convenient to disclose now.” (Cailian Press)